Lubka T Roumenina

List of Publications by Year
in descending order

118	9,366	61945 43	40954 93
papers	citations	h-index	g-index

131	131	131	8749
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Complement System Part I Ã¢â‚¬â€œ Molecular Mechanisms of Activation and Regulation. Frontiers in Immunology, 2015, 6, 262.	2.2	1,161
2	Complement System Part II: Role in Immunity. Frontiers in Immunology, 2015, 6, 257.	2.2	762
3	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney International, 2012, 82, 454-464.	2.6	454
4	Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Reviews Nephrology, 2012, 8, 643-657.	4.1	448
5	Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations. Journal of the American Society of Nephrology: JASN, 2010, 21, 859-867.	3.0	383
6	Endothelium structure and function in kidney health and disease. Nature Reviews Nephrology, 2019, 15, 87-108.	4.1	292
7	Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort. PLoS Medicine, 2011, 8, e1001013.	3.9	240
8	Context-dependent roles of complement in cancer. Nature Reviews Cancer, 2019, 19, 698-715.	12.8	217
9	Complement factor H related proteins (CFHRs). Molecular Immunology, 2013, 56, 170-180.	1.0	214
10	Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood, 2013, 122, 282-292.	0.6	207
11	Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood, 2011, 117, 1340-1349.	0.6	188
12	C1q and its growing family. Immunobiology, 2007, 212, 253-266.	0.8	174
13	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. Cancer Immunology Research, 2019, 7, 1091-1105.	1.6	153
14	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood, 2009, 114, 2837-2845.	0.6	140
15	Alternative complement pathway assessment in patients with atypical HUS. Journal of Immunological Methods, 2011, 365, 8-26.	0.6	140
16	Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight, 2018, 3, .	2.3	135
17	A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood, 2012, 119, 4182-4191.	0.6	128
18	Interaction of C1q with IgG1, C-reactive Protein and Pentraxin 3:Â Mutational Studies Using Recombinant Globular Head Modules of Human C1q A, B, and C Chainsâ€. Biochemistry, 2006, 45, 4093-4104.	1.2	126

#	Article	IF	Citations
19	Heme: Modulator of Plasma Systems in Hemolytic Diseases. Trends in Molecular Medicine, 2016, 22, 200-213.	3.5	126
20	Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood, 2015, 125, 2359-2369.	0.6	112
21	Complement Factor B Mutations in Atypical Hemolytic Uremic Syndromeâ€"Disease-Relevant or Benign?. Journal of the American Society of Nephrology: JASN, 2014, 25, 2053-2065.	3.0	107
22	Antibody Polyreactivity in Health and Disease: Statu Variabilis. Journal of Immunology, 2013, 191, 993-999.	0.4	100
23	Antiâ€"Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases. Journal of Immunology, 2015, 194, 5129-5138.	0.4	99
24	Overall Neutralization of Complement Factor H by Autoantibodies in the Acute Phase of the Autoimmune Form of Atypical Hemolytic Uremic Syndrome. Journal of Immunology, 2012, 189, 3528-3537.	0.4	96
25	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney International, 2017, 92, 1232-1241.	2.6	93
26	B cells and cancer: To B or not to B?. Journal of Experimental Medicine, 2021, 218, .	4.2	91
27	P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6280-6285.	3.3	90
28	Endothelial cells: source, barrier, and target of defensive mediators. Immunological Reviews, 2016, 274, 307-329.	2.8	88
29	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2017, 28, 1603-1613.	3.0	83
30	Antibodies Use Heme as a Cofactor to Extend Their Pathogen Elimination Activity and to Acquire New Effector Functions. Journal of Biological Chemistry, 2007, 282, 26696-26706.	1.6	81
31	Mutational Analyses of the Recombinant Globular Regions of Human C1q A, B, and C Chains Suggest an Essential Role for Arginine and Histidine Residues in the C1q-IgG Interaction. Journal of Immunology, 2004, 172, 4351-4358.	0.4	72
32	Renal Transplantation Under Prophylactic Eculizumab in Atypical Hemolytic Uremic Syndrome With CFH/CFHR1 Hybrid Protein. American Journal of Transplantation, 2012, 12, 1938-1944.	2.6	70
33	An Engineered Construct Combining Complement Regulatory and Surface-Recognition Domains Represents a Minimal-Size Functional Factor H. Journal of Immunology, 2013, 191, 912-921.	0.4	70
34	Loss of DGKÎµ induces endothelial cell activation and death independently of complement activation. Blood, 2015, 125, 1038-1046.	0.6	69
35	Functional and structural insight into properdin control of complement alternative pathway amplification. EMBO Journal, 2017, 36, 1084-1099.	3.5	69
36	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood, 2014, 123, 121-125.	0.6	63

#	Article	IF	Citations
37	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Medicine, 2020, 12, 86.	3.6	63
38	Functional Complement C1q Abnormality Leads to Impaired Immune Complexes and Apoptotic Cell Clearance. Journal of Immunology, 2011, 187, 4369-4373.	0.4	58
39	Complement System: Promoter or Suppressor of Cancer Progression?. Antibodies, 2020, 9, 57.	1.2	58
40	Heme Interacts with C1q and Inhibits the Classical Complement Pathway. Journal of Biological Chemistry, 2011, 286, 16459-16469.	1.6	56
41	Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit. Toxins, 2019, 11, 660.	1.5	55
42	C1q+ macrophages: passengers or drivers of cancer progression. Trends in Cancer, 2022, 8, 517-526.	3.8	51
43	Anti-Factor B Antibodies and Acute Postinfectious GN in Children. Journal of the American Society of Nephrology: JASN, 2020, 31, 829-840.	3.0	50
44	Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. Kidney International, 2021, 99, 581-597.	2.6	48
45	Role of Ca2+in the Electrostatic Stability and the Functional Activity of the Globular Domain of Human C1qâ€. Biochemistry, 2005, 44, 14097-14109.	1.2	46
46	Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. American Journal of Hematology, 2020, 95, 456-464.	2.0	46
47	Existence of Different but Overlapping IgG- and IgM-Binding Sites on the Globular Domain of Human C1qâ€. Biochemistry, 2006, 45, 9979-9988.	1.2	45
48	Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. Journal of Biological Chemistry, 2015, 290, 25343-25355.	1.6	44
49	Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. Haematologica, 2021, 106, 626-629.	1.7	44
50	Coagulome and the tumor microenvironment: an actionable interplay. Trends in Cancer, 2022, 8, 369-383.	3.8	44
51	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunology Research, 2021, 9, 891-908.	1.6	43
52	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Frontiers in Immunology, 2018, 9, 2260.	2.2	42
53	Atypical Hemolytic Uremic Syndrome Associated with Mutations in Complement Regulator Genes. Seminars in Thrombosis and Hemostasis, 2010, 36, 641-652.	1.5	41
54	Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis. Frontiers in Immunology, 2018, 9, 179.	2.2	41

#	Article	IF	Citations
55	Interaction of the globular domain of human C1q with Salmonella typhimurium lipopolysaccharide. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 1271-1276.	1.1	40
56	Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunology Research, 2021, 9, 909-925.	1.6	40
57	A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. Journal of the American Society of Nephrology: JASN, 2016, 27, 1665-1677.	3.0	39
58	Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus antiâ€C1q antibodies by a specific peptideâ€based enzymeâ€linked immunosorbent assay. Arthritis and Rheumatism, 2012, 64, 3706-3714.	6.7	37
59	Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. Frontiers in Immunology, 2018, 9, 3008.	2.2	36
60	A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney International, 2017, 92, 876-887.	2.6	35
61	Iron Ions and Haeme Modulate the Binding Properties of Complement Subcomponent C1q and of Immunoglobulins. Scandinavian Journal of Immunology, 2007, 65, 230-239.	1.3	32
62	Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. Transfusion Clinique Et Biologique, 2019, 26, 116-124.	0.2	32
63	Complement C1qâ€target proteins recognition is inhibited by electric moment effectors. Journal of Molecular Recognition, 2007, 20, 405-415.	1.1	29
64	Genetics of hemolytic uremic syndromes. Presse Medicale, 2012, 41, e105-e114.	0.8	28
65	Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. Nephrology Dialysis Transplantation, 2013, 28, 2899-2907.	0.4	25
66	Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling. Journal of Immunology, 2016, 197, 3669-3679.	0.4	25
67	Analysis of protein missense alterations by combining sequenceâ€and structureâ€based methods. Molecular Genetics & Genomic Medicine, 2020, 8, e1166.	0.6	25
68	Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes. Molecular Medicine, 2015, 21, 1002-1010.	1.9	24
69	Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation. Frontiers in Immunology, 2020, 11, 1684.	2.2	24
70	Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. Frontiers in Immunology, 2021, 12, 680567.	2.2	24
71	Autoantibodies Against C3bâ€”Functional Consequences and Disease Relevance. Frontiers in Immunology, 2019, 10, 64.	2.2	22
72	Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Antiâ€“Factor H IgAÎ» Antibody. American Journal of Kidney Diseases, 2015, 66, 331-336.	2.1	21

#	Article	IF	Citations
73	Site-specific N-glycosylation analysis of soluble FcÎ³ receptor IIIb in human serum. Scientific Reports, 2018, 8, 2719.	1.6	21
74	Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases. International Journal of Molecular Sciences, 2021, 22, 2009.	1.8	19
75	Complement C3 is a novel modulator of the anti-factor VIII immune response. Haematologica, 2018, 103, 351-360.	1.7	17
76	The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction. Transfusion Medicine Reviews, 2019, 33, 225-230.	0.9	16
77	The receptor for advanced glycation end products is a sensor for cellâ€free heme. FEBS Journal, 2021, 288, 3448-3464.	2.2	16
78	Functional Evaluation of Factor H genetic and Acquired Abnormalities: Application for Atypical Hemolytic Uremic Syndrome (aHUS). Methods in Molecular Biology, 2014, 1100, 237-247.	0.4	15
79	A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. Journal of Thrombosis and Haemostasis, 2010, 8, 1524-1531.	1.9	13
80	Mechanism and Functional Implications of the Heme-Induced Binding Promiscuity of IgE. Biochemistry, 2015, 54, 2061-2072.	1.2	13
81	Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. Frontiers in Immunology, 2021, 12, 690821.	2.2	13
82	Chronic histiocytic intervillositis: manifestation of placental alloantibody-mediated rejection. American Journal of Obstetrics and Gynecology, 2021, 225, 662.e1-662.e11.	0.7	13
83	Anti-Factor H Autoantibodies Assay. Methods in Molecular Biology, 2014, 1100, 249-256.	0.4	12
84	Physiological and therapeutic complement regulators in kidney transplantation. Current Opinion in Organ Transplantation, 2013, 18, 421-429.	0.8	11
85	Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival. Inflammation, 2017, 40, 117-122.	1.7	9
86	B cells and complement at the forefront of chemotherapy. Nature Reviews Clinical Oncology, 2020, 17, 393-394.	12.5	9
87	Ex Vivo Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside. Frontiers in Immunology, 2022, 13, 860689.	2.2	9
88	Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme. Molecular Immunology, 2019, 111, 205-208.	1.0	8
89	Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis. Frontiers in Immunology, 2020, 11, 1772.	2.2	8
90	A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein. Frontiers in Immunology, 2018, 9, 2822.	2.2	7

#	Article	IF	Citations
91	Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Molecular Immunology, 2009, 47, 290-297.	1.0	6
92	Plasma C3d levels as a diagnostic marker for complete complement factor I deficiency. Journal of Allergy and Clinical Immunology, 2021, 147, 749-753.e2.	1.5	6
93	Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. Methods in Molecular Biology, 2021, 2227, 191-203.	0.4	5
94	Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H. Pediatric Nephrology, 2019, 34, 533-537.	0.9	4
95	Detection of Autoantibodies to Complement Components by Surface Plasmon Resonance-Based Technology. Methods in Molecular Biology, 2019, 1901, 271-280.	0.4	4
96	Clinical and functional consequences of antiâ€properdin autoantibodies in patients with lupus nephritis. Clinical and Experimental Immunology, 2020, 201, 135-144.	1.1	4
97	Glomerulonephritis With Isolated C3 Deposits as a Manifestation of Subtotal Factor I Deficiency. Kidney International Reports, 2019, 4, 1354-1358.	0.4	3
98	Heme: driver of erythrocyte elimination. Blood, 2021, 138, 1092-1094.	0.6	3
99	1st EFIS-EJI Intensive Course in Clinical Immunology: Towards a new era in Immunology. European Journal of Immunology, 2011, 41, 268-269.	1.6	2
100	Exploration du complÃ©ment : actualitÃ©s 2012. Revue Francophone Des Laboratoires, 2012, 2012, 31-37.	0.0	2
101	The Benefits of Complement Measurements for the Clinical Practice. Methods in Molecular Biology, 2021, 2227, 1-20.	0.4	2
102	Complement factor H: a guardian within?. Kidney International, 2021, 100, 747-749.	2.6	2
103	Terminal complement without C5 convertase?. Blood, 2021, 137, 431-432.	0.6	2
104	A role for complement blockade in kidney transplantation. , 2022, , .		2
105	C3dg-CR3 interaction in erythrophagocytosis. Blood, 2015, 126, 828-829.	0.6	1
106	Detection of Anti-C3b Autoantibodies by ELISA. Methods in Molecular Biology, 2021, 2227, 133-139.	0.4	1
107	Complement C3 Deposition on Endothelial Cells Revealed by Flow Cytometry. Methods in Molecular Biology, 2021, 2227, 97-105.	0.4	1
108	Ex Vivo Complement Activation on Endothelial Cells: Research and Translational Value. Trends in Molecular Medicine, 2021, 27, 418-421.	3.5	1

#	Article	IF	Citations
109	Registration of the Interaction Between C1q Human Complement Derivatives and Immunoglobulins by Elisaâ€"Role of the Solid Phase. Biotechnology and Biotechnological Equipment, 2004, 18, 116-120.	0.5	0
110	Contribution of the C1q Polypeptide Chains in the Recognition of CRP. Biotechnology and Biotechnological Equipment, 2005, 19, 122-125.	0.5	0
111	Intravascular hemolysis induces complement system activation. Molecular Immunology, 2017, 89, 164.	1.0	0
112	Atypical hemolytic uremic syndrome â€" Why the kidney?. Molecular Immunology, 2017, 89, 172-173.	1.0	0
113	FP076ATYPICAL HEMOLYTIC UREMIC SYNDROME - WHY THE KIDNEY?. Nephrology Dialysis Transplantation, 2018, 33, i74-i74.	0.4	0
114	Intratumoral classical complement pathway promotes tumor growth in renal cancer. Molecular Immunology, 2018, 102, 205.	1.0	0
115	LBA29 COMPLEMENT ACTIVATION ORCHESTRATED BY CANCER CELLS AND C1Q-PRODUCING TUMOR ASSOCIATED MACROPHAGES HAS A DELETERIOUS IMPACT ON PATIENTâ€™S PROGNOSIS IN CLEAR CELL RENAL CELL CANCER.. Journal of Urology, 2018, 199, .	0.2	0
116	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A Â«KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMESÂ» (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg), 2018, 22, 18-39.	0.1	0
117	Abstract 2334: Intratumoral classical complement pathway promotes tumor growth in renal cancer. , 2019, , .		0
118	Abstract 2334: Intratumoral classical complement pathway promotes tumor growth in renal cancer. , 2019, , .		0